Year All202620252024202320222021202020192018201720162015201420132012 July 20, 2026 Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 July 20, 2026 Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting July 1, 2026 Harrow Announces Commercial Launch of BYOOVIZ® in the United States June 10, 2026 Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare May 27, 2026 Harrow to Present at William Blair’s 46th Annual Growth Stock Conference May 11, 2026 Harrow Announces First Quarter 2026 Financial Results April 27, 2026 Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026 April 16, 2026 Harrow Announces the Issuance of J-Code for IOPIDINE® 1%